Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.
No podcast episodes available.
CVAC earnings call for the period ending March 31, 2022.
CVAC earnings call for the period ending September 30, 2021.
CVAC earnings call for the period ending March 31, 2021.
CVAC earnings call for the period ending September 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.